Skip to content
10-Q

Quarterly Report

Bellicum Pharmaceuticals, Inc.

0001628280-23-017582

← back to feed
Filed
May 11, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 9, 2023 9.5M sh
Shares Diluted Q1 2023 · Mar 31, 2023 30.83M sh
Shares Diluted Q1 2023 · Mar 31, 2022 30.82M sh
Capex Q1 2023 · Mar 31, 2023 $5K
Capex Q1 2023 · Mar 31, 2022 $7K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$6.43M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$6.38M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $15.4M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $21.84M
Stockholders Equity Q1 2023 · Mar 31, 2023 −$10.02M
Stockholders Equity Q1 2023 · Dec 31, 2022 $2.02M
Stockholders Equity Q1 2023 · Mar 31, 2022 $17.43M
Stockholders Equity Q1 2023 · Dec 31, 2021 $24.4M
Total Liabilities Q1 2023 · Mar 31, 2023 $4.72M
Total Liabilities Q1 2023 · Dec 31, 2022 $3.77M
Current Assets Q1 2023 · Mar 31, 2023 $17.24M
Current Assets Q1 2023 · Dec 31, 2022 $23.8M
Total Assets Q1 2023 · Mar 31, 2023 $17.26M
Total Assets Q1 2023 · Dec 31, 2022 $23.82M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.26
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.25
Eps Basic Q1 2023 · Mar 31, 2023 −$0.26
Eps Basic Q1 2023 · Mar 31, 2022 −$0.25
Sga Expense Q1 2023 · Mar 31, 2023 $1.44M
Sga Expense Q1 2023 · Mar 31, 2022 $1.45M
Rd Expense Q1 2023 · Mar 31, 2023 $7.22M
Rd Expense Q1 2023 · Mar 31, 2022 $4.49M
Net Income Q1 2023 · Mar 31, 2023 −$8.07M
Net Income Q1 2023 · Mar 31, 2022 −$7.56M
Operating Income Q1 2023 · Mar 31, 2023 −$8.65M
Operating Income Q1 2023 · Mar 31, 2022 −$5.94M
Revenue Q1 2023 · Mar 31, 2023 $8K
Revenue Q1 2023 · Mar 31, 2022 $0